文献速递妇科

卵巢癌患者常规胚系BRCA1和BRCA2检测:苏格兰真实世界经验分析

Routine germline BRCA1 and BRCA2 testing in patients with ovarian carcinoma: analysis of the Scottish real-life experience.
PubMed 文献 · BJOG · 2018-05-10

该回顾性队列研究分析了苏格兰四个癌症/遗传中心599例卵巢癌患者的胚系BRCA1/2测序数据,比较2013年前后检测政策变化对突变检出率的影响。新标准下对所有非黏液性卵巢癌患者测序,胚系BRCA1/2突变年检出率从4.2升至20.7,且新标准患者中48%(15/31)的曼彻斯特评分<15,按家族史标准不会接受测序。结论认为对所有非黏液性卵巢癌患者测序可大幅提高年突变检出率,阳性率仍超过10%阈值。

要点

  • 新标准下对所有非黏液性卵巢癌患者测序,胚系BRCA1/2突变年检出率从4.2升至20.7。
  • 新标准组48%(15/31)的胚系BRCA1/2突变患者曼彻斯特评分<15,按家族史标准不会接受测序。
  • >70岁患者胚系BRCA1/2突变患病率为8.2%。

核心结论

  • 对所有非黏液性卵巢癌患者进行测序可大幅提高胚系BRCA1/2突变年检出率,阳性检测频率仍超过许多家族史模型所依据的10%阈值。

研究设计与样本

  • 回顾性队列研究,纳入苏格兰四个癌症/遗传中心599例接受胚系BRCA1/2测序的卵巢癌患者,比较2013年前后检测政策变化前后的情况。
  • 旧标准组205例(2013年前,仅基于家族史选择测序),新标准组236例(2013年后,所有新发非黏液性卵巢癌患者接受测序),流行人群组158例(2013年前发病但不符合旧标准、在新标准下接受测序)。
  • 收集政策变化前及变化后18个月的临床病理和序列数据。

主要发现

  • 旧标准组、新标准组和流行人群组的胚系BRCA1/2突变频率分别为30.7%、13.1%和12.7%。
  • 胚系BRCA1/2突变年检出率在政策变化前为4.2,变化后为20.7。
  • 新标准组中48%(15/31)的胚系BRCA1/2突变患者曼彻斯特评分<15,按家族史标准不会接受测序。
  • 流行人群组中鉴定出20例胚系BRCA1/2突变患者。
  • >70岁患者中胚系BRCA1/2突变患病率为8.2%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the rates of germline BRCA1 and BRCA2 mutations in Scottish patients with ovarian cancer, before and after a change in testing policy. DESIGN: Retrospective cohort study. SETTING: Four cancer/genetics centres in Scotland. POPULATION: Patients with ovarian cancer undergoing germline BRCA1 and BRCA2 (gBRCA1/2) sequencing before 2013 (under the 'old criteria', with selection based solely on family history), after 2013 (under the 'new criteria', with sequencing offered to newly presenting patients with non-mucinous ovarian cancer), and in the 'prevalent population' (who presented before 2013, but were not eligible for sequencing under the old criteria but were sequenced under the new criteria). METHODS: Clinicopathological and sequence data were collected before and for 18 months after this change in selection criteria. MAIN OUTCOME MEASURES: Frequency of germline BRCA1, BRCA2, RAD51C, and RAD51D mutations. RESULTS: Of 599 patients sequenced, 205, 236, and 158 were in the 'old criteria', 'new criteria', and 'prevalent' populations, respectively. The frequency of gBRCA1/2 mutations was 30.7, 13.1, and 12.7%, respectively. The annual rate of gBRCA1/2 mutation detection was 4.2 before and 20.7 after the policy change. A total of 48% (15/31) 'new criteria' patients with gBRCA1/2 mutations had a Manchester score of <15 and would not have been offered sequencing based on family history criteria. In addition, 20 patients with gBRCA1/2 were identified in the prevalent population. The prevalence of gBRCA1/2 mutations in patients aged >70 years was 8.2%. CONCLUSIONS: Sequencing all patients with non-mucinous ovarian cancer gives a much higher annual gBRCA1/2 mutation detection rate, with the frequency of positive tests still exceeding the 10% threshold upon which many family history-based models operate. TWEETABLE ABSTRACT: BRCA sequencing all non-mucinous cancer patients increases mutation detection five fold.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Rust K, Spiliopoulou P, Tang CY, et al. Routine germline BRCA1 and BRCA2 testing in patients with ovarian carcinoma: analysis of the Scottish real-life experience. BJOG. 2018. PMID: 29460478. doi:10.1111/1471-0528.15171

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。